Provided by Tiger Trade Technology Pte. Ltd.

Beam Therapeutics, Inc.

25.23
-0.4400-1.71%
Pre-market: 24.88-0.3500-1.39%09:02 EDT
Volume:2.52M
Turnover:64.38M
Market Cap:2.61B
PE:-30.12
High:26.94
Open:26.80
Low:24.87
Close:25.67
52wk High:38.26
52wk Low:20.23
Shares:103.29M
Float Shares:91.60M
Volume Ratio:1.50
T/O Rate:2.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8376
EPS(LYR):-0.8100
ROE:-8.18%
ROA:-17.01%
PB:2.44
PE(LYR):-31.15

Loading ...

Beam Therapeutics Announces Clearance of Investigational New Drug Application for Beam-304 for the Treatment of Phenylketonuria (Pku) by the United States (U.S.) Food and Drug Administration

THOMSON REUTERS
·
Jun 18

Beam Stockholders Back Board, Leadership at Annual Meeting

TIPRANKS
·
Jun 09

Beam Therapeutics shareholders elect Class III directors at annual meeting

Reuters
·
Jun 09

Beam Therapeutics (BEAM) Gets a Buy from Canaccord Genuity

TIPRANKS
·
May 21

Beam Therapeutics presents Phase 1/2 data for BEAM-302

TIPRANKS
·
May 19

Beam Therapeutics presents Phase 1/2 BEAM-302 AATD trial data at ATS 2026

Reuters
·
May 19

Analysts Conflicted on These Healthcare Names: Omnicell (OMCL), Beam Therapeutics (BEAM) and Zentalis Pharmaceuticals (ZNTL)

TIPRANKS
·
May 13

Beam Therapeutics to present updated BEACON trial biomarker data for risto-cel in SCD at EHA2026

Reuters
·
May 12

Will Beam Therapeutics' (BEAM) Revenue Surge, Pipeline Updates and Added Liquidity Change Its Narrative?

Simply Wall St.
·
May 11

Evercore ISI Sticks to Their Buy Rating for Beam Therapeutics (BEAM)

TIPRANKS
·
May 09

Beam Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
May 07

Beam Therapeutics Q1 net loss narrows beating analyst estimates

Reuters
·
May 07

Beam Q1 FY26 net loss narrows 12.94% to $94.3 million

Reuters
·
May 07

Beam Therapeutics Q1 Operating Expenses USD 138.953 Million

THOMSON REUTERS
·
May 07

Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

GlobeNewswire
·
May 07

A Look At Beam Therapeutics (BEAM) Valuation After TIME Recognition And BEACON Trial Progress

Simply Wall St.
·
May 03

Beam Therapeutics announces annual shareholder meeting via webcast

Reuters
·
Apr 18